In the run-up to his first anniversary as CEO of Sanofi, Chris Viehbacher talked about wresting control from scientists who didn't want to look outside for new ideas or products. "I think we have been able to open up the walls of the company," Viehbacher told the Financial Times in November.
There's no greater example of Viehbacher's push than the billion-dollar expansion of Sanofi's R&D relationship with antibody platform firm
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?